## Remarks

1

Applicants assert that no new matter has been entered as a result of this amendment. No fees are believed to be due with the filing of this amendment. However, if any fees are deemed to be necessary, the Commissioner is hereby authorized to charge any deficiencies to or credit any overpayment to Deposit Account No. 50-1078.

In accordance with Section 714.01 of the M.P.E.P., the following information is presented in the event that a call may be deemed desirable by the Examiner:

JACOB N. ERLICH

(617) 854-4000

Dated: February 18, 2004

Respectfully submitted, Claudia A. Robbins, et al., Applicants

Bv

Jacob N. Erlich Reg. No. 24,338

Attorney for Applicants




Table 2: Typical Purity from Mouse Pancreas Spleen and Thymus (Pel Freez, Rogers, AR) using 0.8 µm MMM columns and QIAGEN RNeasy Mini Kit with associated on-column DNase digestion protocols.

## Purity (pg gDNA/ ng sample)

gDNA contamination (quantitative direct PCR assay)

	(quantitative direct i Cit assay)				
	Inve	Invention		GEN	
	Std. (-	+ DNase	Std. (-	+ DNase	
	DNase)		DNase)		
Pancreas	$1.4 \times 10^{-3}$	1.7 x 10 <sup>-4</sup>	5.2 x 10 <sup>-1</sup>	6.4 x 10 <sup>-2</sup>	
Thymus	$2.7 \times 10^{1}$	3.1 x 10 <sup>-1</sup>	$2.9x\ 10^{2}$	$1.3 \times 10^{2}$	
Spleen	8.3 x 10 <sup>-1</sup>	1.8 x 10 <sup>-1</sup>	$9.2 \times 10^{1}$	$2.7 \times 10^{0}$	

Table 3: Typical yields from various frozen mouse tissues (Pel Freez, Rogers, AR) using 0.8 µm MMM columns and QIAGEN RNeasy Mini Kit.

Y	i	e	1	d

	A <sub>260</sub>				
	Low Load		High Load		
	Invention	QIAGEN	Invention	QIAGEN	
Brain (2.5, 30 mg)	0.6 μg/mg	0.6 μg/mg	0.8 μg/mg	0.8 μg/mg	
Liver (2.5, 30 mg)	4.6 μg/mg	5 μg/mg	4.5 μg/mg	4.6 µg/mg	
Kidney (2.5, 30 mg	2.3 μg/mg	2.9 μg/mg	2.7 μg/mg	2.7 μg/mg	
Spleen (2.5, 15 mg)	3.1 μg/mg	2.5 μg/mg	3.7 µg/mg	2.1 μg/mg	
HeLa (cells) (5 x 10 <sup>5</sup> , 4 x 10 <sup>6</sup> )	13.8 μg/10 <sup>6</sup>	22.8 μg/10 <sup>6</sup>	15.5 μg/10 <sup>6</sup>	16 μg/10 <sup>6</sup>	

Table 4: Typical purity using 8-Layer glass-fiber prefiltration column and subsequent isolation using 0.8 µm MMM columns and QIAGEN RNeasy Mini Kit.

Purity
gDNA Contamination

(quantitative direct PCR assay) Low Load High Load **QIAGEN** Invention Invention **QIAGEN** Brain (2.5, 30 mg)  $1.2 \times 10^{\circ}$  $1.1 \times 10^{2}$  $1.6 \times 10^{0}$  $7.2 \times 10^{9}$ 2.8 x 10<sup>-2</sup>  $1.3 \times 10^{1}$ 1.3 x 10<sup>-1</sup> Liver (2.5, 30 mg) 3.7 x 10<sup>-1</sup> Kidney (2.5, 30 mg) 2.1 x 10<sup>-1</sup>  $5.5 \times 10^{1}$ 8.9 x 10<sup>-1</sup>  $1.5 \times 10^{\circ}$ Spleen (2.5, 15 mg) 2.1 x 10<sup>-1</sup>  $1.9 \times 10^{2}$  $2.0 \times 10^{-1}$  $4.2 \times 10^{1}$ HeLa (cells)  $(5 \times 10^5, 4 \times 10^6)$  $6.8 \times 10^{-2}$  $6.8 \times 10^{1}$  $1.9 \times 10^{0}$  $1.2 \times 10^{1}$ 

Reduction of gDNA contamination is important in many molecular biological assays, in particular, quantitative RT-PCR. RT-PCR is generally a two-step reaction